Top
| Drug resistance assays in leukemias and lymphomas: An introduction | p. 1 |
| Predictive assays in acute leukemia | p. 17 |
| Pharmacologic factors involved in the response to chemotherapy: Apparent versus intrinsic drug resistance | p. 33 |
| MDR1 gene expression: An independent prognostic factor in acute myeloid leukemia | p. 41 |
| Detection of P-glycoprotein in adult AML | p. 49 |
| Evaluation of the MDR phenotype of acute non-lymphoblastic leukemia (ANLL) | p. 55 |
| Multidrug resistance in myelodysplastic syndromes and acute leukemia | p. 59 |
| In vitro chemosensitivity assay (DiSC assay) and P-glycoprotein (P-170) expression for determining the patient's sensitivity pattern | p. 67 |
| Immunocytochemical evaluation of the multidrug resistance associated P-170 glycoprotein in responsive multiple myeloma | p. 73 |
| Western immunoblotting enhanced chemiluminescence (ECL) detection of P-glycoprotein in vinca-alkaloid resistant cell-lines and human leukemic cells | p. 77 |
| MDR1 gene expression in a multidrug resistant human non-Hodgkin's lymphoma xenograft model | p. 89 |
| Double labeling flow cytometry analysis of multidrug resistance in leukemias and lymphomas | p. 95 |
| Clinical impact of P-glycoprotein (PGP)/multidrug resistance (MDR1) and anionic glutathione S-transferase (GSTN) gene expression in non-Hodgkin's lymphoma (NHL) | p. 105 |
| Characterization of the role of cytosolic glutathione S-transferase in the conjugation of glutathione to melphalan | p. 115 |
| Biochemical and electrochemical characterization of acquired drug resistance in human lymphatic malignancy | p. 121 |
| Detection of P-glycoprotein activity in tissue culture and clinical samples using the fluorescent dye rhodamine 123 | p. 131 |
| Non-covalent modulation of topoisomerase II activity and drug sensitivity in human leukemic cells | p. 141 |
| Cyclosporin A, etoposide and mitoxantrone (C.E.M.), a phase I-II trial in advanced acute leukemia (AL): An intermediate analysis | p. 145 |
| Clinical modulation of multidrug-resistant multiple myeloma by cyclosporin | p. 153 |
| Reversal of etoposide resistance with verapamil | p. 161 |
| Effects of cyclosporin A on sensitivity to and cellular accumulation of daunorubicin in fresh leukemic cells: A preliminary report | p. 165 |
| Enhanced verapamil-mediated vincristine accumulation in cycling human B-CLL cells | p. 175 |
| Reversal of MDR1: How to evaluate clinical usefulness of chemosensitizers in vitro | p. 183 |
| Circumvention of multidrug resistance by addition of calcium/calmodulin antagonists to cytostatic drugs | p. 189 |
| Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZPSC833 in Chinese hamster ovary cells expressing the MDR1 phenotype | p. 195 |
| Multidrug resistance modification in myeloid leukemias | p. 201 |
| Chemosensitizing effect of stimulating AML blast cells with myeloid growth factors evaluated with the MTT-assay | p. 207 |
| Effect of GM-CSF on DNA polymerase [alpha] activity and its implication on ara-C metabolism in AML blasts in vitro | p. 215 |
| Handling requirements to achieve active drugs in in vitro drug sensitivity and resistance assays | p. 227 |
| Use of S9 liver microsomes in the DiSC assay to identify drugs requiring activation in vitro | p. 257 |
| Cytotoxic chemotherapeutic agents: Effective in vitro probes for the biology of human cancer | p. 263 |
| Bioflavonoids: A possible tool in the therapy of acute leukemias | p. 271 |
| Use of the MTT-assay for evaluation of chemosensitivity in adult acute myeloid leukemia | p. 279 |
| Resistance patterns of anthracycline analogs in acute myeloid leukemia using the MTT assay | p. 285 |
| Study of drug combinations in acute myeloid leukemia (AML) using the MTT assay | p. 293 |
| Clinical relevance of drug resistance testing with the MTT assay in childhood acute lymphoblastic leukemia (ALL) | p. 299 |
| In vitro chemosensitivity of childhood leukemic cells and the clinical value of assay directed therapy | p. 313 |
| Is resistance to prednisolone in vitro related to the response to prednisolone in vivo at initial diagnosis in childhood acute lymphoblastic leukemia? A preliminary analysis | p. 321 |
| Differences in antileukemic activity and in leukemia type-specific activity of antineoplastic agents in childhood leukemia at initial diagnosis studied with the MTT assay | p. 329 |
| Cellular drug resistance in childhood relapsed acute lymphoblastic leukemia | p. 337 |
| Treatment of children with poor prognosis relapsed acute lymphoblastic leukemia based on individual drug resistance profiles: Procedure | p. 345 |
| Drug resistance testing as a basis for tailored therapy in children with refractory or relapsed acute lymphoblastic leukemia | p. 353 |
| A feasibility study of the MTT assay for chemosensitivity testing in non-Hodgkin's lymphoma (NHL) | p. 359 |
| Acute myeloid leukemia (AML) sensitivity to antiblastics is predictable by INT assay | p. 365 |
| A comparison of two chemosensitivity assays for human acute non-lymphocytic leukemia cells | p. 369 |
| The DiSC assay: 10 years and 2000 tests further on | p. 373 |
| The cross-resistance between radiosensitivity and chemosensitivity of fresh human chronic lymphocytic leukemic lymphocytes using the DiSC assay | p. 385 |
| Preclinical evaluation of cytotoxic drugs using the Rotman fluorescent cytoprint assay | p. 393 |
| Drug sensitivity testing of tumor cells from patients with acute leukemia and non-Hodgkin lymphoma using a fluorometric microculture cytotoxicity assay | p. 399 |
| A new lymphoma chemosensitivity assay | p. 409 |
| Cell culture drug resistance assays in hematologic neoplasms based on the concept of total tumor cell kill | p. 415 |
| Index | p. 433 |
| Table of Contents provided by Blackwell. All Rights Reserved. |
